FDA Grants Approval for Dofetilide ANDA212496 by Innogenix Inc.
The FDA has granted approval for the ANDA212496 application for Dofetilide submitted by Innogenix Inc.
Published: August 5, 2026
Updated: August 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Antiarrhythmic
Asset: Dofetilide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Dofetilide
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Innogenix Inc.'s generic Dofetilide marks a significant shift in the antiarrhythmic drug market, increasing competition and potentially impacting pricing strategies. Existing competitors must adapt to maintain their market share in light of this new entrant.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Innogenix Inc. and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.